10/22/2014 - 2:50pm

The Food and Drug Administration last week announced plans to survey pharmacists and patients about their experiences resulting from changes in generic drug pill appearance.

10/22/2014 - 12:20pm

Pfizer last week announced that the Food and Drug Administration approved a revised label for Embeda (morphine sulfate and naltrexone hydrochloride) extended-release capsules, for oral use, CII, to include abuse-deterrence studies. 

 

10/22/2014 - 9:06am

A JAMA study noted that about two-thirds of dietary supplements recalled by the Food and Drug Administration still contained banned ingredients at least six months after being recalled.

10/17/2014 - 2:58pm

The Congressional Dietary Supplement Caucus hosted an educational briefing and luncheon for congressional staffers on Oct. 14, the day before the 20th anniversary of the passage of the Dietary Supplement Health and Education Act.

10/17/2014 - 2:42pm

With open enrollment for the 2015 health insurance plan year set to begin on Nov. 15, National Association of Chain Drug Stores members were invited by Secretary of Health and Human Services Sylvia Burwell to participate in a pharmacy issues meeting on Friday.

10/16/2014 - 11:52am

The Food and Drug Administration has granted approval to Esbriet (pirfenidone), as well as Ofev (nintedanib), to treat idiopathic pulmonary fibrosis — a condition in which the lungs scar over time.

10/15/2014 - 3:52pm

As the Food and Drug Administration begins to explore ways to improve its user-fee program for generic drugs, the Generic Pharmaceutical Association and its members have weighed in with suggestions on how to shore up the law to ensure that it helps bring generics to market faster and provides benefits across the entire healthcare system.

10/15/2014 - 3:52pm

Could the regulatory and scientific logjam that’s keeping copycat biotech medicines off the market and out of the hands of patients and health providers in the United States finally be breaking?

10/15/2014 - 3:52pm

What’s in a name? A lot, apparently, if the name applies to a biosimilar medicine.